T-Type Channel Druggability at a Crossroads.

Animals Calcium Channel Blockers / administration & dosage Calcium Channels, T-Type / metabolism Clinical Trials as Topic / methods Drug Delivery Systems / methods Drug Discovery / methods Humans Nervous System Diseases / drug therapy
Calcium channels Cav3 channels T-type channels drug discovery epilepsy neuron neuropathic pain pharmacology

Journal

ACS chemical neuroscience
ISSN: 1948-7193
Titre abrégé: ACS Chem Neurosci
Pays: United States
ID NLM: 101525337

Informations de publication

Date de publication:
20 03 2019
Historique:
pubmed: 31 1 2019
medline: 7 3 2020
entrez: 31 1 2019
Statut: ppublish

Résumé

Low-voltage activated T-type calcium channels mediate essential functions in the nervous system, and alteration of channel activity is causally linked to a number of neurological conditions. Therefore, T-type channels hold great promise as pharmacological targets for new medicines. In this Viewpoint, we discuss the potential of T-type channels as druggable targets and reevaluate the strategies available for developing therapeutically efficient and specific modulators of this channel.

Identifiants

DOI: 10.1021/acschemneuro.9b00031 PMID: 30697997
pubmed: 30697997
doi: 10.1021/acschemneuro.9b00031
doi:

Substances chimiques

Calcium Channel Blockers 0
Calcium Channels, T-Type 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1124-1126

Auteurs

Norbert Weiss (N)

Institute of Organic Chemistry and Biochemistry , Czech Academy of Sciences , Prague 166 10 , Czech Republic.

Gerald W Zamponi (GW)

Hotchkiss Brain Institute and Alberta Children's Hospital Research Institute, Cumming School of Medicine , University of Calgary , Calgary T2N4N1 , Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › T-Type Channel Druggability at a Crossroads.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents cardiovasculaires › Inhibiteurs des canaux calciques › T-Type Channel Druggability at a Crossroads.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Canaux ioniques › Canaux calciques › Canaux calciques de type T › T-Type Channel Druggability at a Crossroads.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › T-Type Channel Druggability at a Crossroads.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › T-Type Channel Druggability at a Crossroads.
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › T-Type Channel Druggability at a Crossroads.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › T-Type Channel Druggability at a Crossroads.
questionsmedicales.fr › Maladies du système nerveux › T-Type Channel Druggability at a Crossroads.